Quick Facts
| Property | Value |
|---|---|
| Category | Regenerative Peptide Blend |
| Risk Level | Low/Moderate |
| Administration | Subcutaneous Injection |
| Typical Frequency | Daily |
| Estimated Half-Life | Blend-Dependent / Multi-Phase Activity |
| Primary Research Interest | Tissue Repair / Recovery / Injury Support |
This material is provided strictly for educational and informational purposes related to peptide research and regenerative compounds. The “Wolverine Stack” (BPC-157 / TB-500) is an experimental peptide blend with limited large-scale human safety data. Information presented here should not be interpreted as medical advice, treatment recommendations, or encouragement of unsupervised use.
1. Reconstitution Guide
- Blend Composition: BPC-157 5 mg / TB-500 5 mg
- Blend Ratio: 1 : 1
- Total Vial Size: 10 mg total blend
- Dilutant Type: BAC Water
- Amount of Dilutant Added: 2 mL
- Final Concentration: 5 mg/mL total blend concentration
At this concentration:
• 10 units = 0.10 mL
• 20 units = 0.20 mL
2. Route of Administration
The “Wolverine Stack” is most commonly administered as a subcutaneous injectable regenerative peptide blend.
- Primary Route: SubQ Injection
- Alternative Practices Discussed: Near-injury injections are commonly discussed in anecdotal communities
- Administration Notes: Systemic subcutaneous administration remains the most widely recognized use pattern
3. Typical Research Protocols
- Product Strength: 5 mg/mL total blend concentration
- Typical Delivered Amount: 10–20 units daily
- Frequency: Daily
- Cycle Length: 8–12 weeks on, PRN (as needed) for injury recovery
- Special Notes: Site-of-injury or “near injury” injection is very common in anecdotal discussions. However, evidence supporting true site-specific targeting remains limited. Systemic subcutaneous injection is the most widely recognized administration approach.
4. Summary
The “Wolverine Stack” combines BPC-157 and TB-500 into a dual regenerative peptide blend intended to support tissue repair, inflammation modulation, soft tissue recovery, and recovery from musculoskeletal injury.
The combination is popular within regenerative peptide discussions because both compounds are believed to influence overlapping but complementary recovery pathways.
5. Mechanism of Action
The blend combines two experimental regenerative peptides:
- BPC-157: Angiogenesis support, tissue repair signaling, inflammation modulation
- TB-500: Cellular migration support, actin regulation, tissue remodeling
Together, the blend is commonly discussed as supporting:
- Soft tissue recovery
- Tendon and ligament repair signaling
- Inflammation reduction
- Recovery from musculoskeletal stress
- Enhanced tissue remodeling
6. Potential Benefits
- Potential tendon and ligament recovery support
- Improved soft tissue healing signaling
- Reduced inflammation
- Enhanced recovery from injury or training stress
- Potential improvements in mobility and recovery comfort
7. Potential Risks / Side Effects
Low/Moderate
- Injection site irritation
- Fatigue
- Nausea
- Headaches
- Potential abnormal angiogenesis concerns
- Limited long-term human safety data
- Unknown long-term regenerative signaling effects
8. Half-Life
Because this blend contains multiple peptides, half-life discussions vary between compounds.
BPC-157 is commonly discussed as relatively short acting, while TB-500 may exert longer downstream tissue signaling effects.
9. Storage Information
- Store refrigerated before and after reconstitution
- Protect from direct light exposure
- Avoid repeated freeze-thaw cycles
- Maintain sterile handling practices during preparation
10. Contraindications / Warnings
- Active cancer or cancer history
- Pregnancy or breastfeeding
- Use alongside experimental angiogenic compounds
- Known hypersensitivity to peptide compounds
11. Research References
- PubMed
- NIH Publications
- Experimental regenerative medicine literature
- Peer-reviewed tissue repair journals
CKF Tide Tables 